Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/109181
Título: | The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? | Autor: | Godinho, Ricardo Mega, Cristina Teixeira-Lemos, Edite Carvalho, Eugenia Teixeira, Frederico Fernandes, Rosa Reis, Flávio |
Data: | 2015 | Editora: | Hindawi | Projeto: | PTDC/SAU-OSM/104124/2008 Pest-C/SAU/ LA0001/2013 UID/NEU/04539/2013 (CNC.IBILI) PROTEC-SFRH/BD/50139/2009 |
Título da revista, periódico, livro ou evento: | Journal of Diabetes Research | Volume: | 2015 | Resumo: | Incretin-based therapies, the most recent therapeutic options for type 2 diabetes mellitus (T2DM) management, can modify various elements of the disease, including hypersecretion of glucagon, abnormal gastric emptying, postprandial hyperglycaemia, and, possibly, pancreatic β cell dysfunction. Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) increase glucagon-like peptide-1 (GLP-1) availability and correct the "incretin defect" seen in T2DM patients. Clinical studies have shown good glycaemic control with minimal risk of hypoglycaemia or any other adverse effects, despite the reports of pancreatitis, whose association remains to be proved. Recent studies have been focusing on the putative ability of DPP-4 inhibitors to preserve pancreas function, in particular due to the inhibition of apoptotic pathways and stimulation of β cell proliferation. In addition, other cytoprotective effects on other organs/tissues that are involved in serious T2DM complications, including the heart, kidney, and retina, have been increasingly reported. This review outlines the therapeutic potential of DPP-4 inhibitors for the treatment of T2DM, focusing on their main features, clinical applications, and risks, and discusses the major challenges for the future, in particular the possibility of becoming the preferred therapy for T2DM due to their ability to modify the natural history of the disease and ameliorate nephropathy, retinopathy, and cardiovascular complications. | URI: | https://hdl.handle.net/10316/109181 | ISSN: | 2314-6745 2314-6753 |
DOI: | 10.1155/2015/806979 | Direitos: | openAccess |
Aparece nas coleções: | I&D CNC - Artigos em Revistas Internacionais I&D IBILI - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
The-Place-of-Dipeptidyl-Peptidase4-Inhibitors-in-Type-2-Diabetes-Therapeutics-A-Me-Too-or-the-Special-One-Antidiabetic-ClassJournal-of-Diabetes-Research.pdf | 2.17 MB | Adobe PDF | Ver/Abrir |
Visualizações de página
75
Visto em 28/ago/2024
Downloads
19
Visto em 28/ago/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons